Search Results - "VARDENY, ORLY"

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 by Vaduganathan, Muthiah, Vardeny, Orly, Michel, Thomas, McMurray, John J.V, Pfeffer, Marc A, Solomon, Scott D

“…The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors…”
Get full text

Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis by Bloomfield, Hanna E., Greer, Nancy, Linsky, Amy M., Bolduc, Jennifer, Naidl, Todd, Vardeny, Orly, MacDonald, Roderick, McKenzie, Lauren, Wilt, Timothy J.

“…Background Polypharmacy and use of inappropriate medications have been linked to increased risk of falls, hospitalizations, cognitive impairment, and death…”
Get full text

Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure by Vardeny, Orly, PharmD, MS, Miller, Ryan, BS, Solomon, Scott D., MD

“…Abstract Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds…”
Get full text

Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation by Savarese, Gianluigi, Kishi, Takuya, Vardeny, Orly, Adamsson Eryd, Samuel, Bodegård, Johan, Lund, Lars H., Thuresson, Marcus, Bozkurt, Biykem

“…Guidelines recommend early initiation of multiple guideline-directed medical therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart…”
Get full text

Trends in prevalence of comorbidities in heart failure clinical trials by Khan, Muhammad Shahzeb, Samman Tahhan, Ayman, Vaduganathan, Muthiah, Greene, Stephen J., Alrohaibani, Alaaeddin, Anker, Stefan D., Vardeny, Orly, Fonarow, Gregg C., Butler, Javed

“…ABSTRACT Aims The primary objective of this systematic review was to estimate the prevalence and temporal changes in chronic comorbid conditions reported in…”
Get full text

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure by Vardeny, Orly, PharmD, MS, Wu, Dong Hong, PhD, Desai, Akshay, MD, MPH, Rossignol, Patrick, MD, Zannad, Faiez, MD, Pitt, Bertram, MD, Solomon, Scott D., MD

“…Objectives This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spironolactone in patients with severe heart…”
Get full text

Cardiovascular implications of COVID-19 versus influenza infection: a review by Khan, Muhammad Shahzeb, Shahid, Izza, Anker, Stefan D, Solomon, Scott D, Vardeny, Orly, Michos, Erin D, Fonarow, Gregg C, Butler, Javed

“…Due to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients…”
Get full text

Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial by Solomon, Scott D, Lowenstein, Charles J, Bhatt, Ankeet S, Peikert, Alexander, Vardeny, Orly, Kosiborod, Mikhail N, Berger, Jeffrey S, Reynolds, Harmony R, Mavromichalis, Stephanie, Barytol, Anya, Althouse, Andrew D, Luther, James F, Leifer, Eric S, Kindzelski, Andrei L, Cushman, Mary, Gong, Michelle N, Kornblith, Lucy Z, Khatri, Pooja, Kim, Keri S, Baumann Kreuziger, Lisa, Wahid, Lana, Kirwan, Bridget-Anne, Geraci, Mark W, Neal, Matthew D, Hochman, Judith S

“…COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express…”
Get full text

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials by Fiuzat, Mona, Hamo, Carine E., Butler, Javed, Abraham, William T., DeFilippis, Ersilia M., Fonarow, Gregg C., Lindenfeld, Joann, Mentz, Robert J., Psotka, Mitchell A., Solomon, Scott D., Teerlink, John R., Vaduganathan, Muthiah, Vardeny, Orly, McMurray, John J.V., O’Connor, Christopher M.

“…With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which…”
Get full text

Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities) by Bello, Natalie A, Cheng, Susan, Claggett, Brian, Shah, Amil M, Ndumele, Chiadi E, Roca, Gabriela Querejeta, Santos, Angela B S, Gupta, Deepak, Vardeny, Orly, Aguilar, David, Folsom, Aaron R, Butler, Kenneth R, Kitzman, Dalane W, Coresh, Josef, Solomon, Scott D

“…Obesity increases cardiovascular risk. However, the extent to which various measures of body composition are associated with abnormalities in cardiac structure…”
Get full text

Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial by Marshall, Nell J, Lee, Jennifer L, Schroeder, Jessica, Lee, Wei-Nchih, See, Jermyn, Madjid, Mohammad, Munagala, Mrudula R, Piette, John D, Tan, Litjen, Vardeny, Orly, Greenberg, Michael, Liska, Jan, Mercer, Monica, Samson, Sandrine

“…Seasonal influenza affects 5% to 15% of Americans annually, resulting in preventable deaths and substantial economic impact. Influenza infection is…”
Get full text

An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality by Seidelmann, Sara B, Vardeny, Orly, Claggett, Brian, Yu, Bing, Shah, Amil M, Ballantyne, Christie M, Selvin, Elizabeth, MacRae, Calum A, Boerwinkle, Eric, Solomon, Scott D

“…Elevated B-type natriuretic peptide (BNP) levels are associated with heart failure and increased mortality in the general population. We investigated rs198389,…”
Get full text

Resistance to antihypertensive treatment and long‐term risk: The Atherosclerosis Risk in Communities study by Wijkman, Magnus O., Malachias, Marcus V.B., Claggett, Brian L., Cheng, Susan, Matsushita, Kunihiro, Shah, Amil M., Jhund, Pardeep S., Coresh, Josef, Solomon, Scott D., Vardeny, Orly

“…More stringent blood pressure (BP) goals have led to greater prevalence of apparent resistant hypertension (ARH), yet the long‐term prognostic impact of ARH…”
Get full text

Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance by Vardeny, Orly, Hernandez, Adrian F, Cohen, Lauren W., Franklin, Amy, Baqai, Mina, Palmer, Sarah, Bierer, Barbara E, Cobb, Nichelle

“…Background/Aims Obtaining ethical approval from multiple institutional review boards is a long-standing challenge to multi-site clinical trials and often leads…”
Get full text

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials by Bhatt, Ankeet S, Vaduganathan, Muthiah, Claggett, Brian L, Kulac, Ian J, Anand, Inder S, Desai, Akshay S, Fang, James C, Hernandez, Adrian F, Jhund, Pardeep S, Kosiborod, Mikhail N, Sabatine, Marc S, Shah, Sanjiv J, Vardeny, Orly, McMurray, John J V, Solomon, Scott D, Gaziano, Thomas A

“…The sodium glucose cotransporter-2 inhibitors are guideline-recommended to treat heart failure across the spectrum of left ventricular ejection fraction;…”
Get full text

Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study by Modin, Daniel, Claggett, Brian, Jørgensen, Mads Emil, Køber, Lars, Benfield, Thomas, Schou, Morten, Jensen, Jens-Ulrik Stæhr, Solomon, Scott D, Trebbien, Ramona, Fralick, Michael, Vardeny, Orly, Pfeffer, Marc A, Torp-Pedersen, Christian, Gislason, Gunnar, Biering-Sørensen, Tor

“…Background Influenza infection may increase the risk of stroke and acute myocardial infarction (AMI). Whether influenza vaccination may reduce mortality in…”
Get full text

Influenza vaccine in cardiovascular disease: time to move the needle by Vardeny, Orly

Get full text

Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network by Milfred-LaForest, Sherry K., PharmD, BCPS, Chow, Sheryl L., PharmD, FCCP, BCPS (AQ Card), DiDomenico, Robert J., PharmD, Dracup, Kathleen, RN, PhD, Ensor, Christopher R., PharmD, BCPS (AQ Card), Gattis-Stough, Wendy, PharmD, Heywood, J. Thomas, MD, Lindenfeld, JoAnn, MD, Page, Robert L., MSPH, PharmD, FCCP, BCPS, Patterson, J. Herbert, PharmD, FCCP, Vardeny, Orly, PharmD, MS, BCACP, Massie, Barry M., MD

“…Abstract Background Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple…”
Get full text

The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors by Vardeny, Orly

“…Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of medications that reduce plasma glucose concentrations through an insulin-independent…”
Get full text

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction by Mohanty, April F, Levitan, Emily B, King, Jordan B, Dodson, John A, Vardeny, Orly, Cook, James, Herrick, Jennifer S, He, Tao, Patterson, Olga V, Alba, Patrick R, Russo, Patricia A, Obi, Engels N, Choi, Michelle E, Fang, James C, Bress, Adam P

“…Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for…”
Get full text